Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus

OBJECTIVE: The management of systemic lupus erythematosus (SLE) flares can incur substantial healthcare costs. In the phase III BLISS-SC trial, subcutaneous (SC) belimumab 200 mg plus standard therapy was associated with significant reductions in time to severe flare, and risk of flares, versus plac...

Descripción completa

Detalles Bibliográficos
Autores principales: Lokhandwala, Tasneem, Yue, Binglin, Coutinho, Anna D, Bell, Christopher F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Epidemiology and Outcomes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871685/
https://www.ncbi.nlm.nih.gov/pubmed/33558436
http://dx.doi.org/10.1136/lupus-2020-000438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871685/
https://www.ncbi.nlm.nih.gov/pubmed/33558436
http://dx.doi.org/10.1136/lupus-2020-000438

Ejemplares similares